Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a Comment »
A new study on relative rates of survival at 10 years, just published on line, is probably going to get differing reactions from patients and from physicians depending on their individual points of view.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: comparative, mortality, outcome, survival | 7 Comments »
Whatever we may think individually about the recent decision by the U.S. Preventive Services Task Force to recommend against the use of PSA testing as a means of “screening” for risk of prostate cancer, we would be wise to understand that at the heart of this decision is poor science.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: PSA, risk, screening, survival, USPSTF | 29 Comments »
A population-based analysis of mortality data for men diagnosed with prostate cancer from three European nations suggests that “a small but important group of older patients” initially present with late stage prostate cancer and die rapidly as a consequence.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, elderly, mortality, stage, survival | 11 Comments »
According to a company media release, the full results of the ALSYMPCA trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, outcome, radium, radium-223, survival | Leave a Comment »
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a Comment »
As we have noted several times before, databases in selected European nations (most particularly the Scandinavian countries) allow for the possibility of highly accurate analyses of information on the diagnosis, management, and outcomes of prostate cancer (and other disorders) over time based on data from very large numbers of people.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Denmark, Diagnosis, mortality, outcome, survival | 3 Comments »
As we have previously reported, the latest analysis of survival data from the pivotal Phase III trial of abiraterone acetate + predisone has shown a slight improvement in the survival benefit for patients treated with abiraterone (Zytiga™).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, circulating tumor cell, CTC, survival, Zytiga | Leave a Comment »
A story on the Bloomberg.com web site gives information about a patient with castration-resistant prostate cancer (CRPC) who has had a zero-level PSA for 40 months since starting on a clinical trial of abiraterone actetate in early 2008.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, CRPC, orteronel, survival, TAK-700 | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site